Secukinumab-induced subacute-cutaneous lupus erythematosus Secukinumab-induzierter subakut-kutaner Lupus erythematodes
Wehrmann C, Sondermann W, Körber A (2018)
Publication Type: Journal article
Publication year: 2018
Journal
Book Volume: 69
Pages Range: 64-66
Journal Issue: 1
DOI: 10.1007/s00105-017-4071-8
Abstract
We report about a 52-year-old woman with onset of drug-induced lupus erythematosus (DILE) in sun-exposed areas, under therapy with secukinumab. Topical therapy with a steroid class 3 for 4 weeks showed substantial improvement. The systemic therapy was switched to ustekinumab. DILE is a rare but notable side effect of biologicals in 0.5–1% of the patients and also possible under therapy with IL-17 inhibition. Switch of the biological agent is necessary in most cases.
Involved external institutions
Germany (DE)How to cite
APA:
Wehrmann, C., Sondermann, W., & Körber, A. (2018). Secukinumab-induced subacute-cutaneous lupus erythematosus Secukinumab-induzierter subakut-kutaner Lupus erythematodes. Hautarzt, 69(1), 64-66. https://doi.org/10.1007/s00105-017-4071-8
MLA:
Wehrmann, C., W. Sondermann, and A. Körber. "Secukinumab-induced subacute-cutaneous lupus erythematosus Secukinumab-induzierter subakut-kutaner Lupus erythematodes." Hautarzt 69.1 (2018): 64-66.
BibTeX: Download